853679-43-3

Basic information

• Product Name: 4-(5-AMINO-6-CHLORO-4-PYRIMIDINYL)-1-PIPERAZINECARBOXYLIC ACID 1,1-DIMETHYLETHYL ESTER
• Synonyms: 4-(5-AMINO-6-CHLORO-4-PYRIMIDINYL)-1-PIPERAZINECARBOXYLIC ACID 1,1-DIMETHYLETHYL ESTER;1-Boc-4-(5-amino-6-chloro-4-pyrimidinyl)piperazine;tert-Butyl 4-(5-amino-6-chloropyrimidin-4-yl)piperazine-1-carboxylate
• CAS NO: 853679-43-3
• Molecular Formula: C₁₃H₂₀ClN₅O₂
• Molecular Weight: 313.78
• Mol File: 853679-43-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 468.299°C at 760 mmHg
• Flash Point: 237.019°C
• Appearance: /
• Density: 1.304g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.581
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(5-AMINO-6-CHLORO-4-PYRIMIDINYL)-1-PIPERAZINECARBOXYLIC ACID 1,1-DIMETHYLETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(5-AMINO-6-CHLORO-4-PYRIMIDINYL)-1-PIPERAZINECARBOXYLIC ACID 1,1-DIMETHYLETHYL ESTER(853679-43-3)
• EPA Substance Registry System: 4-(5-AMINO-6-CHLORO-4-PYRIMIDINYL)-1-PIPERAZINECARBOXYLIC ACID 1,1-DIMETHYLETHYL ESTER(853679-43-3)

Safety Data

• Hazardous Substances Data: 853679-43-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H20ClN5O2/c1-13(2,3)21-12(20)19-6-4-18(5-7-19)11-9(15)10(14)16-8-17-11/h8H,4-7,15H2,1-3H3

Upstream product

• 5413-85-4 5-amino-4,6-dichloropyridimine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 853679-45-5 4-(5H-pyrrolo[3,2-d]pyrimidin-4-yl)-piperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Antiviral Activity of Novel Bicyclic Heterocycles

The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of viral disorders and pathologic conditions such as, but not limited to, viral infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus.

AKT PROTEIN KINASE INHIBITORS

The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.